Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel Free IZTC Stock Alerts

Invizyne Technologies (IZTC) Competitors

Invizyne Technologies logo
$9.75 -0.23 (-2.30%)
As of 05/1/2026
Compare

IZTC vs. NVCT, PLYX, ALXO, KROS, and HRTX

Should you be buying Invizyne Technologies stock or one of its competitors? The main competitors of Invizyne Technologies include Nuvectis Pharma (NVCT), Polaryx Therapeutics (PLYX), ALX Oncology (ALXO), Keros Therapeutics (KROS), and Heron Therapeutics (HRTX). These companies are all part of the "pharmaceutical products" industry.

How does Invizyne Technologies compare to Nuvectis Pharma?

Invizyne Technologies (NASDAQ:IZTC) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invizyne TechnologiesN/AN/AN/AN/AN/A
Nuvectis PharmaN/AN/A-$26.44M-$1.32N/A

In the previous week, Nuvectis Pharma had 4 more articles in the media than Invizyne Technologies. MarketBeat recorded 5 mentions for Nuvectis Pharma and 1 mentions for Invizyne Technologies. Nuvectis Pharma's average media sentiment score of 0.03 beat Invizyne Technologies' score of 0.00 indicating that Nuvectis Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Invizyne Technologies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Nuvectis Pharma
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

96.8% of Nuvectis Pharma shares are owned by institutional investors. 30.5% of Nuvectis Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nuvectis Pharma has a consensus price target of $10.00, suggesting a potential upside of 2.99%. Given Nuvectis Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Nuvectis Pharma is more favorable than Invizyne Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Invizyne Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Nuvectis Pharma
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Invizyne Technologies' return on equity of 0.00% beat Nuvectis Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Invizyne TechnologiesN/A N/A N/A
Nuvectis Pharma N/A -143.91%-92.79%

Summary

Nuvectis Pharma beats Invizyne Technologies on 7 of the 9 factors compared between the two stocks.

How does Invizyne Technologies compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Company Net Margins Return on Equity Return on Assets
Polaryx TherapeuticsN/A N/A N/A
Invizyne Technologies N/A N/A N/A

Polaryx Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 120.26%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Polaryx Therapeutics is more favorable than Invizyne Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Polaryx Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Invizyne Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Polaryx TherapeuticsN/AN/AN/AN/AN/A
Invizyne TechnologiesN/AN/AN/AN/AN/A

In the previous week, Polaryx Therapeutics and Polaryx Therapeutics both had 1 articles in the media. Polaryx Therapeutics' average media sentiment score of 0.00 equaled Invizyne Technologies'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Polaryx Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Invizyne Technologies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Polaryx Therapeutics beats Invizyne Technologies on 3 of the 3 factors compared between the two stocks.

How does Invizyne Technologies compare to ALX Oncology?

ALX Oncology (NASDAQ:ALXO) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Invizyne Technologies' return on equity of 0.00% beat ALX Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
ALX OncologyN/A -182.01% -113.63%
Invizyne Technologies N/A N/A N/A

ALX Oncology currently has a consensus price target of $4.60, suggesting a potential upside of 138.34%. Given ALX Oncology's stronger consensus rating and higher possible upside, research analysts clearly believe ALX Oncology is more favorable than Invizyne Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ALX Oncology
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Invizyne Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ALX OncologyN/AN/A-$101.69M-$1.90N/A
Invizyne TechnologiesN/AN/AN/AN/AN/A

98.0% of ALX Oncology shares are owned by institutional investors. 21.0% of ALX Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, ALX Oncology had 3 more articles in the media than Invizyne Technologies. MarketBeat recorded 4 mentions for ALX Oncology and 1 mentions for Invizyne Technologies. Invizyne Technologies' average media sentiment score of 0.00 beat ALX Oncology's score of -0.26 indicating that Invizyne Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ALX Oncology
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Invizyne Technologies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

ALX Oncology beats Invizyne Technologies on 6 of the 9 factors compared between the two stocks.

How does Invizyne Technologies compare to Keros Therapeutics?

Keros Therapeutics (NASDAQ:KROS) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Keros Therapeutics has a net margin of 35.65% compared to Invizyne Technologies' net margin of 0.00%. Keros Therapeutics' return on equity of 14.25% beat Invizyne Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Keros Therapeutics35.65% 14.25% 13.27%
Invizyne Technologies N/A N/A N/A

Keros Therapeutics currently has a consensus price target of $21.33, suggesting a potential upside of 81.25%. Given Keros Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Keros Therapeutics is more favorable than Invizyne Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Keros Therapeutics
1 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.33
Invizyne Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Keros Therapeutics has higher revenue and earnings than Invizyne Technologies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Keros Therapeutics$244.06M0.95$87.01M$1.826.47
Invizyne TechnologiesN/AN/AN/AN/AN/A

71.6% of Keros Therapeutics shares are owned by institutional investors. 22.9% of Keros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Keros Therapeutics had 1 more articles in the media than Invizyne Technologies. MarketBeat recorded 2 mentions for Keros Therapeutics and 1 mentions for Invizyne Technologies. Keros Therapeutics' average media sentiment score of 0.52 beat Invizyne Technologies' score of 0.00 indicating that Keros Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Keros Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Invizyne Technologies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Keros Therapeutics beats Invizyne Technologies on 11 of the 11 factors compared between the two stocks.

How does Invizyne Technologies compare to Heron Therapeutics?

Invizyne Technologies (NASDAQ:IZTC) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Invizyne Technologies has a net margin of 0.00% compared to Heron Therapeutics' net margin of -13.04%.

Company Net Margins Return on Equity Return on Assets
Invizyne TechnologiesN/A N/A N/A
Heron Therapeutics -13.04%N/A -4.62%

Heron Therapeutics has a consensus price target of $4.50, suggesting a potential upside of 265.85%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than Invizyne Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Invizyne Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Heron Therapeutics
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20

In the previous week, Heron Therapeutics had 1 more articles in the media than Invizyne Technologies. MarketBeat recorded 2 mentions for Heron Therapeutics and 1 mentions for Invizyne Technologies. Heron Therapeutics' average media sentiment score of 0.22 beat Invizyne Technologies' score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Invizyne Technologies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Heron Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

80.0% of Heron Therapeutics shares are held by institutional investors. 5.9% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Invizyne Technologies has higher earnings, but lower revenue than Heron Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invizyne TechnologiesN/AN/AN/AN/AN/A
Heron Therapeutics$154.90M1.50-$20.19M-$0.13N/A

Summary

Heron Therapeutics beats Invizyne Technologies on 8 of the 10 factors compared between the two stocks.

Get Invizyne Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for IZTC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IZTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IZTC vs. The Competition

Export
MetricInvizyne TechnologiesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$60.96M$328.15M$6.25B$11.77B
Dividend YieldN/AN/A2.74%5.26%
P/E RatioN/AN/A24.9123.23
Price / SalesN/A189.48504.5675.49
Price / CashN/A22.4443.3053.90
Price / BookN/A4.739.676.69
Net IncomeN/A-$132.96M$3.55B$332.64M
7 Day Performance-5.43%6.97%1.70%2.01%
1 Month Performance11.56%4.03%5.62%9.19%
1 Year Performance-10.47%37.44%34.42%39.59%

Invizyne Technologies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IZTC
Invizyne Technologies
N/A$9.75
-2.3%		N/AN/A$60.96MN/AN/A29
NVCT
Nuvectis Pharma
0.5268 of 5 stars		$8.54
-0.2%		$10.00
+17.1%		N/A$236.84MN/AN/A8
PLYX
Polaryx Therapeutics
N/A$4.88
-7.0%		$10.00
+104.9%		N/A$229.51MN/AN/A11
ALXO
ALX Oncology
3.4645 of 5 stars		$1.69
-0.6%		$4.60
+172.2%		N/A$227.41MN/AN/A40
KROS
Keros Therapeutics
4.0743 of 5 stars		$11.49
+3.3%		$21.33
+85.7%		N/A$227.36M$244.06M6.31100

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:IZTC) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel